Navigation Links
NIH scientist to receive Ross Prize in Molecular Medicine
Date:4/23/2014

John J. O'Shea, M.D., scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has been named the 2014 recipient of the Ross Prize in Molecular Medicine, conferred by the Feinstein Institute's peer-reviewed, open-access journal Molecular Medicine. The award will be given on June 9 at the New York Academy of Sciences in Manhattan, followed by scientific presentations by Dr. O'Shea and other prominent researchers. NIAMS is part of the National Institutes of Health.

The award, which includes a $50,000 prize from Feinstein Institute board members Robin and Jack Ross, is bestowed upon an active investigator who has produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine.

"John's scientific achievements in molecular immunology have been transformative. His work exemplifies the bridge between basic research and clinical practice. We are very proud of John and congratulate him on this honor," said NIAMS Director Stephen I. Katz, M.D., Ph.D.

Dr. O'Shea has been a physician and immunologist at NIH for 33 years. He has made fundamental discoveries related to the signaling of cytokines, molecules that are critical for the development and functioning of the immune system. His research also has focused on the molecular cause of primary immunodeficiencies, inherited conditions in which immune function is impaired, and the genetic basis of autoinflammatory disorders, conditions in which the body attacks its own tissues. He was awarded a U.S. patent for his work on Janus family kinase inhibitors as a new class of immunosuppressive drugs. Dr. O'Shea developed a Cooperative Research and Development Agreement with the pharmaceutical company Pfizer, which generated one such compound that is approved for the treatment of rheumatoid arthritis.

Dr. O'Shea graduated Phi Beta Kappa from St. Lawrence University, Canton, N.Y., and he received an M.D. from the University of Cincinnati. After completing his residency in internal medicine at the State University of New York Upstate Medical University, Syracuse, he received subspecialty training in allergy and immunology at NIH. He was appointed chief of the NIAMS Molecular Immunology and Inflammation Branch in 2002, and became scientific director of the NIAMS Intramural Research Program in 2005. Dr. O'Shea has been the recipient of numerous awards and is a Fellow of the American Association for the Advancement of Science.


'/>"/>

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
Source:Eurekalert

Related medicine news :

1. Scientists identify cancer specific cell for potential treatment of gastric cancer
2. Scientists pinpoint protein that could improve small cell lung cancer therapies
3. AMP publishes curriculum recommendations for medical laboratory scientists
4. Scientists alter fat metabolism in animals to prevent most common type of heart disease
5. Scientists discover a new way to enhance nerve growth following injury
6. Scientists find key steps linking dietary fats and colon cancer tumor growth
7. Stanford scientists identify source of most cases of invasive bladder cancer
8. Scientists discover brains anti-distraction system
9. Scientists find new way to fight malaria drug resistance
10. Stanford scientists develop playbook for reverse engineering tissue
11. Scientists unlock secrets of protein produced by disease-causing fungus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: an ... of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a ... by Reverend Mark Hardy , “While sitting up in bed, I felt a pounding ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear ... political games that circumvent health needs of over 30 million. Many interviews with Dr. ... and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... This month, ... announced that the name of their drug rehab center in Delray Beach, Florida has ... recognize that not only stars such as Philip Seymour Hoffman and Chris Farley are ...
(Date:1/19/2017)... New York (PRWEB) , ... January 19, 2017 ... ... high definition dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with their ... newly designed product is an extension to RMT technology that delivers HD, dynamic, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it will be co-hosting ... in innovative excipients and drug delivery solutions to health industries worldwide. The one ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Pfizer joins Astex, AstraZeneca, ... Consortium   Major research investment to ...   The Milner Therapeutics Institute today ... a partner to the Milner Therapeutics Consortium. Pfizer has ... transfer of materials between industry and academia and allocation ...
(Date:1/19/2017)... , January 19, 2017 The global  pacemaker market ... report by Grand View Research, Inc. The heightening prevalence of cardiac conditions coupled ... growth of Pacemaker globally. In addition, technological enhancements in these devices are supporting ... ... Grand View Research Logo ...
(Date:1/19/2017)... LONDON , Jan. 18, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
Breaking Medicine Technology: